NEW YORK, Aug 6 - Synaptic Pharmaceutical of Paramus, NJ, said it planned to raise $41 million in two stages of private financing.

Under the terms of the deal, investment firm Warburg Pincus has agreed to purchase 2.2 million series B preferred shares representing 19.9 percent of the company’s stock for $9.4 million. Warburg Pincus has also agreed to purchase additional convertible shares valued at $31.6 million in a second tranche combining series B and C preferred stock.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.